Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 3/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17357042 | 0.85 | TSHR (0.54) | TSHRCETPPOLBFOLH1ALDH1A1 | |
| SCHEMBL13228165 | 0.84 | TSHR (0.45) | TSHRCETPPOLBFOLH1 | |
| SCHEMBL5669129 | 0.84 | TSHR (0.55) | TSHRCETPFOLH1NPC1RAB9A | |
| SCHEMBL4634504 | 0.81 | TSHR (0.51) | TSHRCETPFOLH1NPC1RAB9A | |
| SCHEMBL17359394 | 0.78 | POLB (0.46) | POLBLMNAELANEL3MBTL1 | |
| SCHEMBL11302597 | 0.77 | ELANE (0.51) | TSHRCETPPOLBFOLH1NPC1 | |
| SCHEMBL13892565 | 0.76 | TSHR (0.56) | TSHRCETPPOLBFOLH1NPC1 | |
| SCHEMBL14139643 | 0.75 | TSHR (0.45) | TSHRCETPFOLH1LMNA | |
| SCHEMBL7383180 | 0.75 | TSHR (0.47) | TSHRCETPFOLH1RAB9AALDH1A1 | |
| SCHEMBL11303293 | 0.74 | TSHR (0.55) | TSHRCETPPOLBFOLH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296703-B2 | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150368208-A1 | Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors | UNIVERSITY OF UTAH | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368208-A1 | Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors | BTK, SYK, LYN | TSHR 792/4885CETP 3761/4885ABCB1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.